Table 1.

SPA binding to bead‐associated α₄β₁ integrin and inhibition of Jurkat E6.1 cell adhesion of the reference compound BIO1211 and hybrid α/β‐peptidesa to VCAM‐1 (2 μg·mL⁻¹) or FN (10 μg·mL⁻¹).

Compound	SPA IC50 (nM)b	Cell adhesion Jurkat/VCAM‐1 IC50 (nM)	Cell adhesion Jurkat/FN IC50 (nM)
BIO1211	8.80 ± 3.4 (0.08–46.7) c	4.60 ± 3.0 (0.05–25.1)	5.50 ± 4.0 (0.09–37.6)
DS‐70	8.3 ± 3.2 (0.1–37.2)	5.04 ± 0.51 (0.05–37.3)	4.3 ± 1.7 (0.04–23.4)
DS‐23	47.7 ± 4.1 (4.6–161.4)	40.3 ± 7.1 (3.4–127.6)	51 ± 5.0 (4.8–192.4)

^a Results were generated by measuring, in a cell‐free SPA, the inhibition of [¹²⁵I]‐FN binding by the assayed compounds on Jurkat E6.1 cell lysates in the presence of 10 increasing concentrations of each compound (10⁻¹²–10⁻³ M) and a fixed amount of radioligand (100 000 counts per minute).

^b Six independent experiments were run in quadruplicate.

Data are expressed as means ± SD (with ^c95% confidence limits).